Fusion Pharmaceuticals — Investor Presentation (June 2022)
33 slides from Fusion Pharmaceuticals's investor presentation, Jun 9, 2022
Slide 1: Corporate Presentation June 2022
Corporate Presentation June 2022 Copyright © 2021 Fusion Pharmaceuticals Inc. All Rights Reserved Exhibit 99.2
Slide 2: Forward-Looking Statements and Legal Disclaimers
Forward-Looking Statements and Legal Disclaimers This presentation contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements that are based on our management's belief and assumptions and on info
Slide 3: Radiopharmaceutical Resurgence
Radiopharmaceutical Resurgence Copyright © 2021 Fusion Pharmaceuticals Inc. All Rights Reserved Radiopharmaceuticals are poised to become one of the primary pillars of modern cancer therapy Simple, proven MOA to kill cancer cells through direct DNA damage Technology advancements and clinical data ha
Slide 4: Vision for Fusion Pharmaceuticals
Vision for Fusion Pharmaceuticals Enables the rapid creation of TATs from multiple classes of targeting molecules: Our Targeted Alpha Therapy (TAT) Platform Differentiate by pursuing validated cancer targets and areas of high unmet medical need Leverage internal R&D expertise and use multiple vector
Slide 5: Fusion's Platform Supports Multiple Development Opportunities
Fusion’s Platform Supports Multiple Development Opportunities Discovery Preclinical/ IND Enabling Phase 1 Phase 2 Phase 3 FPI-1434 FPI-1966 FPI-2059 (IPN-1087) FPI-1434 Combination Peptides Targets not disclosed Novel TATs (Up to 3) Targets not disclosed Solid Tumors Expressing IGF-1R Solid Tumors E
Slide 6: Fusion's Radiopharmaceutical & Oncology Drug Development Expertise
Fusion’s Radiopharmaceutical & Oncology Drug Development Expertise Copyright © 2021 Fusion Pharmaceuticals Inc. All Rights Reserved CTO Eric Burak, PhD CFO John Crowley, CPA CHIEF OF STAFF Cara Ferreira, PhD CEO John Valliant, PhD CMO James O’Leary, MD PRESIDENT & CBO Mohit Rawat CLO Maria Stahl, JD
Slide 7: Programs
Programs Fusion’s growing and diverse portfolio Copyright © 2021 Fusion Pharmaceuticals Inc. All Rights Reserved Antibodies: FPI-1434, FPI-1966, Bispecific antibody via AZ collaboration Small Molecules: FPI-2059 Peptides: Discovery partnerships Combinations: Pharma collaborations
Slide 8: TATs as Next Generation Antibody Drug Conjugates (ADCs)
TATs as Next Generation Antibody Drug Conjugates (ADCs) SPECT and Fluorodeoxyglucose (FDG) PET Scans TAT Uptake (left) FDG Uptake (right) …correlates to… Theranostic Imaging De-risks TAT Development vs Biopsy “Whole body view of target expression” 1Nature Reviews, Clinical Oncology 18, 2021 https://
Slide 9: Fast-Clear Linker Enables Development of Next Generation Antibody-Based TATs
Fast-Clear™ Linker Enables Development of Next Generation Antibody-Based TATs Cancer Cell Uptake Within Targeted Tumor Cells Excretion Uptake In Non- Target Tissues Rapid Reduction 225Ac Lysosomal Degradation 225Ac 225Ac Excretion Excretion Process ANTIBODY PROGRAMS Tumor agnostic targets (IGF-1R) V
Slide 10: FPI-1434: Targeting Insulin-like Growth Factor Receptor (IGF-1R)
FPI-1434: Targeting Insulin-like Growth Factor 1 Receptor (IGF-1R) IGF-1R Expression in Solid Tumors 100% Ovarian 100% Bladder 90% Sarcomas 62% Head & Neck 62% Prostate 59% NSCLC 57% Pancreatic 50% Colorectal 50% Liver 47% Breast 43% Small Cell Lung 40% Esophagus 36% Renal 36% ACC IGF-1R: Attractive
Slide 11: FPI-1434: Phase 1 Theranostic Safety Study in Solid Tumors Expressing IGF-1R
FPI-1434: Phase 1 Theranostic Safety Study in Solid Tumors Expressing IGF-1R PHASE 1 MULTI-DOSE (DOSE ESCALATION) PHASE 1 SINGLE-DOSE* (DOSE ESCALATION) 12 patients dosed-tumor uptake seen in multiple tumor types 3 dose cohorts up to 40kBq/kg completed with good safety profile No DLTs, treatment-rel
Slide 12: Antibody-Based Radiopharmaceuticals
Antibody-Based Radiopharmaceuticals Copyright © 2021 Fusion Pharmaceuticals Inc. All Rights Reserved Antibody based therapies (ADCs, radiopharmaceuticals) have shown positive clinical data A number of recent successes Emerging data supports the use of antibodies for radiopharmaceuticals including TA
Slide 13: Pre-Administration of Cold Ab Can Enhance Tumor Delivery/Dose of RPT
Pre-Administration of Cold Ab Can Enhance Tumor Delivery/Dose of Radiopharmaceutical Therapies (RPT) Copyright © 2021 Fusion Pharmaceuticals Inc. All Rights Reserved Examples of RPT Dosing Regimens 225Ac-J591: 225Ac-J591 composed of cold antibody at 20 mg; RP2D of 93.3 kBq/kg (Tagawa et al, JCO 2018
Slide 14: What about for 1434?
What about for 1434? NHP study whereby we add cold to enhance AUC and marrow exposure and then evaluate toxicity Copyright © 2021 Fusion Pharmaceuticals Inc. All Rights Reserved In our original NHP toxicity studies we pushed to toxicity and saw myelosuppression (reversible and recoverable) These res
Slide 15: Clinical Imaging Data Supports Enhanced Tumor Uptake and T:B Ratios
Clinical Imaging Data Supports Enhanced Tumor Uptake and T:B Ratios Copyright © 2021 Fusion Pharmaceuticals Inc. All Rights Reserved Cold Antibody Sub-Study Use imaging to assess impact of cold antibody at different levels prior to hot+cold therapy studies Study was completed and supported initiatin
Slide 16: FPI-1966: Targeting Fibroblast Growth Factor Receptor 3 (FGFR3)
FGFR3 is a validated target addressing a large market opportunity FPI-1966: Targeting Fibroblast Growth Factor Receptor 3 (FGFR3) FGFR3 is a Validated Target: FDA approved pan-FGFR inhibitor for the treatment of bladder cancer Limited to specific genetic alterations Potential for resistance developm
Slide 17: FPI-1966 Development Program: Initiating with a Multi Dosing Regimen
PHASE 1 MULTI-DOSE ESCALATION In patients with advanced solid tumors expressing FGFR3 FPI-1966 Development Program: Initiating with a Multi Dosing Regimen ANTIBODY PROGRAMS Cohort 1A: FPI-1966 Dose 1: 10kBq/kg Cohort 1B: Vofatamab Low Dose + FPI-1966 Dose 1 Cohort 1C: Vofatamab Mid Dose + FPI-1966 D
Slide 18: Opportunity to build on momentum in prostate cancer therapy with alpha radiation
Opportunity to build on momentum in prostate cancer therapy with the power of alpha radiation Small molecule radiopharmaceuticals have shown positive Phase 3 data for subset of prostate cancer patients with high PSMA expression (1)(2) There is a need and opportunity for a next gen radiopharm for tho
Slide 19: FPI-2059: A small molecule TAT targeting NTSR1
FPI-2059: A small molecule TAT targeting NTSR1 SMALL MOLECULE PROGRAMS Fusion acquired the small molecule 177Lu radiopharmaceutical, IPN-1087, from Ipsen Human imaging data Promising early clinical safety data 225Ac-IPN-1087 Shows Single Dose Tumor Kill In Preclinical Models Imaging Shows Targeted U
Slide 20: Combination Therapies: Potential to Lower Doses, Expand Markets
COMBINATION THERAPIES: Potential to Lower Doses, Expand Markets & Enable TATs to Move to Earlier Lines of Therapy Making I/O “resistant/cold” tumors “sensitive/hot” Abscopal effect seen on distal lesions (preclinical data) Potential to expand utility of checkpoint inhibitors and address tumor hetero
Slide 21: Vaccine effect indicates synergistic effects of combining with I/O
“Vaccine effect” indicates synergistic effects of combining with I/O and supports opportunity expand market Fusion is Pioneering TAT + I/O Research Treat Re-Challenge CT-26 No Treatment Tumor/ Spleen Assessment Immune Competent Mouse CT-26 Colorectal Tumor (muIGF-1R++, CTLA++, PD-1+ Tumor) Untreated
Slide 22: Combination of Sub-Therapeutic Single Agent Doses Enhanced Anti-Tumor Activity
Combination of Sub-Therapeutic Single Agent Doses Resulted in Enhanced Anti-Tumor Activity Synergistic Efficacy Has been observed in multiple tumor xenograft models Supports opportunity to expand DDRi market Synergy FPI-1434 + Olaparib FPI-1434 + Olaparib PARP Insensitive Tumor Combination of FPI-14
Slide 23: Collaboration Agreement with AZ Expands & Diversifies Pipeline
Collaboration Agreement with AZ Expands & Diversifies Pipeline 2) Up to 5 Combination Therapies with TATs DNA Damage Response Inhibitors (DDRis) Immuno-oncology agents AZ solely funds unless Fusion opts-in 1) 3 Novel Targeted Alpha Therapies Co-fund Co-develop Option to co-commercialize in U.S. Vali
Slide 24: Peptide Programs: Comprehensive Set of Tools to Create Novel TATs
Fusion has created TATs from antibodies and small molecules that bind to validated cancer targets New partnership agreements provide access to discovery tools needed to create de novo TATs leveraging Fusion’s platform and internal expertise Adding the capability to develop peptide-based TATs gives F
Slide 25: Preferential & Global Manufacturing Relationships
Preferential & Global Manufacturing Relationships Actinium Supply and Manufacturing Expertise and Capacity are Critical Success Factors in Radiopharmaceutical Development Multiple partners support redundancy and scalability Optimized tech transfer process enables Fusion to complete CMC for IND appro
Slide 26: Financials and Key Milestones
Financials and Key Milestones
Slide 27: Financial Highlights as of 3/31/2022
Scalable Capacity to Support Multiple Programs with TAT Platform Financial Highlights as of 3/31/2022 $206.7M Cash, Cash Equivalents and Investments Balance Sheet Cash to Fund Operations into Q1 2024* Expected Cash Runway Outstanding 43.2M Basic Common Shares *Includes cash, cash equivalents and inv
Slide 28: Future Milestones by Program
Future Milestones by Program Milestone Timing* FPI-2059 IND Submission Q2 2022 FPI-1966 First Patient Treated 2H 2022 FPI-1434 Phase 1 Multi-Dose Data 1H 2023 FPI-1434 Combo Studies 6 – 9 months post-RP2D in mono FPI-1966 Cohort 1 Data TBD *Timelines assume no additional disruptions of pre-clinical
Slide 29: De Novo Targeted Alpha Therapy (TAT) Development
De Novo Targeted Alpha Therapy (TAT) Development Development of TATs is a rapidly emerging field akin to immuno and cell therapies in the past Beta-emitting radiopharmaceuticals against popular targets like PSMA have been in patients since the 1990’s (antibodies) and early 2000s (small molecule PSMA
Slide 30: Summary
Summary Pursuing large markets with differentiated targets Internal R&D and a platform, including proprietary FastClear™ linker technology, that is not limited by targeting modality (antibodies, small molecules, peptides, and combos) Deep and diverse pipeline including multiple clinical-stage produc
Slide 31: Appendix
Appendix www.FusionPharma.com Copyright © 2021 Fusion Pharmaceuticals Inc. All Rights Reserved
Slide 32: Potency of TATs | FPI-1434 Single Dose Eradicated Tumors in Mice
Potency of TATs | FPI-1434 Single Dose Eradicated Tumors in Mice Single Dose Eradicated Tumors in Preclinical Model (CRC xenograft mouse model) Histological Eradication of Tumors by Pathology (H&E tumor cell staining following treatment) Control: No effect, dark purple tumor cells present Naked anti
Slide 33: Promising Preclinical Data Support Advancing to Phase 1 Study
Promising Preclinical Data Support Advancing to Phase 1 Study Fast-Clear™ Linker connects vofatamab, a human monoclonal antibody that targets FGFR3, with actinium-225 Vofatamab previously demonstrated safety and good tolerability in patients with advanced bladder cancer (study of >150 patients) FPI-
Fusion Pharmaceuticals — Investor Presentation (June 2022) on 6ix